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Abstract 
Modulated electro-hyperthermia (mEHT) is a form of hyperthermia used in the treatment of cancer. It is a 
variation that relies on a particular form of enhanced selectivity to enable more effective cancerous cell 
death yet maintaining the integrity of healthy non-cancerous cells. It is yet to successfully make the major 
step into the wider medical community despite several encouraging trials. In this study, we investigate 
mEHT from an in vitro perspective. We demonstrate a supra-additive effect on 9 L gliosarcoma cells when 
exposed to mEHT in combination with MV X-ray radiation. The supra-additive effect is hypothesized to be 
induced by the mEHT mechanism that in turn causes apoptosis, membrane damage and an increase in 
rate of cell growth. This proves to be extremely advantageous in the case of the aggressive 9 L cell line as 
it is known to be radioresistant. However, the universal success of this multimodal treatment does not 
appear to be positive for all cell lines and requires further research. Due to the fundamental approach 
taken in this research, our results also provide a new prospect for mEHT to be a tool for sterilizing 
otherwise radioresistant cancers. 
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First in vitro evidence of modulated 
electro-hyperthermia treatment 
performance in combination 
with megavoltage radiation by 
clonogenic assay
Marjorie McDonald  1,2, Stéphanie Corde  1,2,3, Michael Lerch1,2, Anatoly Rosenfeld1,2, 
Michael Jackson1,3 & Moeava Tehei  1,2
Modulated electro-hyperthermia (mEHT) is a form of hyperthermia used in the treatment of cancer. It 
is a variation that relies on a particular form of enhanced selectivity to enable more effective cancerous 
cell death yet maintaining the integrity of healthy non-cancerous cells. It is yet to successfully make 
the major step into the wider medical community despite several encouraging trials. In this study, 
we investigate mEHT from an in vitro perspective. We demonstrate a supra-additive effect on 9 L 
gliosarcoma cells when exposed to mEHT in combination with MV X-ray radiation. The supra-additive 
effect is hypothesized to be induced by the mEHT mechanism that in turn causes apoptosis, membrane 
damage and an increase in rate of cell growth. This proves to be extremely advantageous in the case 
of the aggressive 9 L cell line as it is known to be radioresistant. However, the universal success of this 
multimodal treatment does not appear to be positive for all cell lines and requires further research. Due 
to the fundamental approach taken in this research, our results also provide a new prospect for mEHT to 
be a tool for sterilizing otherwise radioresistant cancers.
Hyperthermia uses active heating to treat cancer, either alone, or in combination with other modalities such as 
radiotherapy or chemotherapy1,2.
Despite conventional hyperthermia technology being used since the early 1900s, benefit is not widely accepted 
in conventional clinical practice. This is mainly attributed to hyperthermia’s limitation in transferring heat to deep 
tissue and its ability to focus this transfer of heat energy only on malignant cells3. Other limitations of hyperther-
mia include the limited correlation between temperature and the heat energy that is being delivered. This makes 
it problematic to control and supply sufficient energy to the target tissue.
Capacitive radiofrequency (RF) hyperthermia uses an alternative electric field to heat areas of the body 
and has been widely used in conventional practice in Korea and Japan. In Germany, it is most often used in 
complimentary clinics. A frequency of 13.56 MHz is often used as it provides reasonable penetration into the 
body without the need for electromagnetic shielding of the device and its public availability. mEHT differs from 
conventional capacitive heating in that a special fractal modulation of the carrier frequency is claimed to give 
enhanced the selection of the tumour cells in the target and allow the use of much lower applied power levels 
than other similar devices. It also may overcome the limited penetration of 13.56 MHz energy in human tissues 
especially through the subcutaneous fat and allow the treatment of sites such as the brain and close to the eye 
which can be difficult to treat with other external techniques. Tumour temperature is not measured directly but 
calculated form input power and other factors4. The actual penetration of the 13.56 MHz energy is disputed in the 
literature and the typical racial differences (until recent times) in subcutaneous fat distribution may partly explain 
the popularity of the different methods5,6.
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The cell membrane maintains the integrity of cells by providing a barrier between the cell and the extracellular 
environment. mEHT has been designed to selectively autofocus electromagnetic power mainly on malignant cell 
membranes, which result in the breakage of the membranes4. The selection is based on the abnormality of the 
metabolic processes of cellular connections and the organising pattern of malignant cells from their correspond-
ing healthy cells. Therefore, the characteristics mentioned above are believed to allow for the autofocus heating 
of the membrane rafts of malignant cells. In addition, the non-ionizing electromagnetic waves can penetrate into 
deep tissue, which allows for the maintenance of energy absorption in a desired locality7.
External beam radiotherapy is one of the predominant treatment modalities used today in cancer treatment. 
Higher megavoltage (MV) photon beams have been dominantly used in clinical oncology because of its effec-
tive treatment of deep-seated cancer, which makes MV beams the current interest among academic studies8. 
Radiation therapy uses high-energy electromagnetic radiation to shrink tumours and kill cancer cells9. Radiation 
therapy alone can destroy cancer cells by inducing significant damage (directly or indirectly) on their deoxyri-
bonucleic acid (DNA). In many cases the damage to the DNA is short-lived as the DNA is naturally repaired. 
Extensive research has been invested into improving the efficiency in damaging the DNA.
The application of hyperthermia has been established as a complementary treatment to most of the tradi-
tional treatment modalities10,11. It has been shown to provide synergies with most of the traditional treatment 
modalities, which include radiation therapy11–13. Conventional hyperthermia combined with radiotherapy has 
been reported to improve clinical response, local control and the survival in randomised trials for patients with 
breast, head and neck cancers, skin melanoma and glioblastoma multiform14,15. However, it should be emphasized 
that there are many factors which can affect the overall complete response rate in patients16,17. The efficiency of 
radiotherapy is oxygen dependent. This means those tumours that are severely hypoxic are more resistant to 
radiation treatment. Therefore, one of hyperthermia’s role is to increase blood perfusion (oxygenation) of the 
tumour through the increased temperatures18,19. Hyperthermia is also more effective in hypoxic conditions. This 
subsequently increases sensitisation to radiation ionisation. The positive impact of hyperthermia in combination 
with radiotherapy is evident in clinical results13,15,16. However, there are disappointing clinical trials as well20,21. 
The controversial clinical results and unexplained underlying mechanisms including risks and safety issues of 
hyperthermia are its challenges in oncology. This multimodal application and its challenges are also extended to 
mEHT treatment. mEHT has been clinically shown to be successful as monotherapy as well as complementing 
with radiation therapy and chemotherapy4. Despite the positive trials on mEHT, medical communities soundly 
did not consider these results conclusive. Moreover, there are only a limited number of studies done in-vitro, thus 
it invites for more studies to be conducted.
In this study, we aimed to use clonogenic assay as a key experiment to help verify the effectiveness of mEHT 
treatment at the cellular level when combined with radiation. Aggressive gliosarcoma and metastatic breast can-
cer cell lines along with a non-cancerous cell line are utilised in this research. This will be the first study in mEHT 
to employ radiobiological clonogenic assay along with real time imaging to provide independent evidence on 
the efficiency of the treatment. The effectiveness of mEHT will be assessed both alone and in combination with 
radiation therapy.
Results
mEHT damages cell of 9L immediately after treatment but not on MCF-7 and MDCK. Confocal 
images with Propidium iodine (PI) staining were taken to test the selectivity of mEHT on the cancer cell. PI is a 
membrane impermeant dye used to detect dead cells or cells with compromised cell membranes.
The selective effect of mEHT is only observed in the 9 L cell line at the 0 hour time point (see Figs 1, 2 and 3). 
The 9 L cells appeared healthy in the images taken at 6, 12, and 24 hours. This implies that repair may take place 
shortly after the mEHT treatment. Conversely, damage induced by mEHT at the 0 hour was not observed for the 
MCF-7 results (see Fig. 3). As expected, there was no damage observed to the MDCK cell line (see Fig. 1) due to 
the selectivity of mEHT as reported in the literature for other non-cancerous cell lines4.
mEHT induces change in cell growth and their growth rate. MDCK cell line. After exposure 
to mEHT treatment, the trend for the curve of the cell growth of mEHT treated cells in the initial 12 hours is 
decreasing relative to the untreated cell control group (see Fig. 4a.1). It should be stressed that the actual con-
fluence value is not decreasing for the mEHT treatment, but rather it is the value normalised to the control group 
that is decreasing. Within this 12-hour window, the response of the cell growth to the treatment is temporarily 
stagnant whilst the control group’s confluence increases in a stable manner. After 12 hours, the mEHT treated 
cells displayed an active response and this is evident in the more rapid fluctuation in the rate of cell growth (see 
Fig. 4a.2). Therefore, this results in the final growth curve converging to the same number of cells relative to the 
control group (shown in Fig. 4a.1).
9L cell line. For this cell line, the mEHT treated cells’ growth curve is trending towards resumption of normal 
cell growth (see Fig. 4b.1). As the data was normalised to the control group, the results indicate the change in the 
cell proliferation (growth) rate. The rate of change in cell growth also increases in a near monotonic manner (see 
Fig. 4b.2). Hence this explains the phenomena of the observed cell growth curve as seen in Fig. 4b.1). Even if the 
proliferation is decreased just after the mEHT treatment, our results however indicate no added advantage for 
mEHT treatment alone on malignant 9 L cells in the first 35 hours post treatment.
MCF-7 cell lines. The data seems to be a combination of what was observed with the 9 L and MDCK cell lines. 
The mEHT treated group exhibited a similar trend for confluence outcome for the MCF-7 cell line. That is, 
long-term behaviour showed that the treated cells are converging to the control confluence value. This is evi-
dent in the trend of their cells growth curve (see Fig. 4c.1) and rate of change in the growth (see Fig. 4c.2). The 
www.nature.com/scientificreports/
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convergence of the growth curve to the same number of control cells was detected at 35 hours, as shown in 
Fig. 4c.1. Nonetheless, the rate of change in the MCF-7 cells growth were relatively bounded compared to 9 L and 
MDCK (see Figs 4a.2 and 4b.2). This is seen by smaller fluctuations around the normalised mark (Fig. 4c.2) in 
comparison to 9 L (Fig. 4b.2) where the curve appeared to be monotonically increasing. This suggests that MCF-7 
cells may have a higher resistance to mEHT treatment than 9 L cells over this time period.
As the mEHT treated cells provided a similar terminal confluence value (to the control group) in the 35-hour 
time period for both MCF-7 and 9 L, this confirms our findings that mEHT provides no increased cell death at 
Figure 1. MDCK cells time-lapse images of cells with and without (control) 30-minute treatment of mEHT. 
Propidium iodine dye (fluorescing in red) was added to the cells immediately before taking the confocal 
microscope imaging. The assay was performed twice.
www.nature.com/scientificreports/
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the conclusion of this timeframe. However, the observed fluctuation in cell growth rate in the malignant cell 
line (9 L) induced by mEHT could be beneficial if the cells were more sensitive to radiation in the more rapidly 
growing phase.
The selectivity of mEHT on malignant cells is not evident in the initial 96 hours. This section 
incorporates real-time imaging to analyse beyond the time points of the results in 2.a) and 2.b). Additionally, we 
are co-culturing both the non-malignant and malignant cells to investigate the selectivity of mEHT in co-culture. 
Figure 2. 9 L cells time-lapse Images of cells with and without (control) 30-minute treatment of mEHT. 
Propidium iodine dye (fluorescing in red) was added to the cells immediately before taking the confocal 
microscope imaging. The assay was performed twice.
www.nature.com/scientificreports/
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As the co-cultured cells began to adhere to the surface and proliferate, their structure became more distinct which 
allowed for the distinguishing of the two cell lines in the IncuCyte images. This was first observed at the 48-hour 
mark (Figs 5 and 6). The 72-hour and 96-hour images displayed a co-existence of both MDCK and a particular 
malignant cell line (either MCF-7 or 9 L) in both the control and the mEHT treatment group, as shown in Fig. 5 
(MDCK co-cultured with 9 L) and Fig. 6 (MDCK co-cultured with MCF-7). The co-existence demonstrated that 
the mEHT treatment did not have selectivity for the malignant cells within this extended timeframe.
Figure 3. MCF-7 cells time-lapse Images of cells with and without (control) 30-minute treatment of mEHT. 
Propidium iodine dye (fluorescing in red) was added to the cells immediately before taking the confocal 
microscope imaging. The assay was performed twice.
www.nature.com/scientificreports/
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mEHT is not very effective as a sole method of treatment. The clonogenic assay results presented 
here, obtained after 15 doubling times of each cell line investigated show that the MDCK cells have a high survival 
fraction for the mEHT treatment at (81 ± 4)%. The 9 L cells showed a larger difference in the survival fraction 
compared to the control with a value of (75 ± 18)%. The MCF-7 cells showed a greater apparent sensitivity to the 
mEHT treatment, with a survival fraction of (61 ± 12)%. The difference in the survival fraction between the two 
malignant cell lines is within their respective uncertainties (refer to the error bars in Fig. 7). However, if the trend 
for reduced proliferation in MCF-7 compared to 9 L cells is real, this may due to mEHT inducing a short-term 
cell membrane damage for 9 L cells whereas it induced a more long-term impact on the cells’ biological properties 
(e.g., capacity to divide and proliferate) in MCF-7 cells.
mEHT and radiation treatments have synergistic effects on 9L but not on MCF7 or MDCK. The 
survival fraction results for MDCK showed a marginal contribution of mEHT pre-treatment when used in 
Figure 4. MDCK (a), 9 L (b) and MCF-7 (c) cell lines were plated in 36-well plates after mEHT treatment at 
the same starting density. After allowing cells to adhere to the plate for 2 hours, cells were then monitored for 
confluence in an IncuCyte imager over the timescale shown, where (a.1, b.1, c.1) treated cells confluence relative 
to control and (a.2, b.2, c.2) rate of change in treated cell confluence relative to control. The data was normalised 
to the control (untreated cells) for comparison of the curves. Results from six replicated wells are shown. Error 
bars indicate ± SEM. The 35-hour time period was chosen as it corresponds to the highest doubling time of our 
studied cells (i.e. 9 L).
www.nature.com/scientificreports/
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combination with a radiation dose of 5 Gy compared to the case where radiation is used alone (see Fig. 8a). The 
SF obtained for radiation alone and its combination with mEHT were (5.4 ± 0.2)% and (4.4 ± 0.2)% respectively. 
The SF of 9 L cells for radiation alone and its combination with mEHT were (35 ± 1)% and (13 ± 1)% respectively. 
This is a substantial decrease (Fig. 8b); indicating a supra-additive effect. The 9 L cell line is well known to be very 
resistant to radiation so this result makes it potentially clinically significant.
Despite the fact that MCF-7 showed a lower cell survival fraction than 9 L when treated with mEHT alone (see 
Fig. 7), a similar outcome is not observed in the mEHT combined with radiation treatment. This was expected 
because MCF-7 cells demonstrated resistance to mEHT as evident with the PI dye staining image (see Fig. 3) 
and the cells confluence rate of change (see Fig. 4c.2). The survival fractions of MCF-7 cells under exposure to 
Figure 5. IncuCyte imaged of co-cultured of MDCK and 9 L cells with and without (control) mEHT treatment 
growth over a period of 96 hours. The same cells density was seeded into 24-well plates and images were taken 
every 24 hours. A representative example of the results from six replicated wells is shown.
www.nature.com/scientificreports/
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radiation alone and mEHT treatment combined with radiation was (7 ± 1)% and (6 ± 2)% respectively (Fig. 8c). 
The results yielded no enhancement of the combined mEHT and radiation treatment on this radiosensitive 
malignant cell line.
Figure 6. IncuCyte imaged of co-cultured of MDCK and MCF-7 cells with and without (control) mEHT 
treatment growth over a period of 96 hours. The same cells density was seeded into 24-well plates and images 
were taken every 24 hours. A representative example of the results from six replicated wells is shown.
www.nature.com/scientificreports/
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Discussion
mEHT kills malignant cells by apoptosis through external (membrane) signal path22. The images of mEHT treated 
cells with PI staining demonstrate the damaged membranes at the immediate time point (i.e., at the 0 hour) on 
the aggressive 9 L cells; however, no additional membrane damage was evident for the MCF-7 cell line when 
compared to the control without treatment. This suggests that the effect of mEHT treatment is not universal 
across different tumours cell lines. This is consistent with a reported set of results where it was shown that the 
mEHT treatment is effective only on the most aggressive cells lines4. However, this bias in which aggressive cell 
line it targets more effectively is not specified in the mEHT literature. Additionally, the time lapse images taken 
for both 9 L and MCF-7 after 0 hours indicate a different process that might be occurring within the cells as their 
membrane integrity was maintained right up to the 24-hour test period. This is inconsistent with the literature 
that demonstrated that mEHT destabilises the cell membrane and increases its permeability4. The observation 
in our results indicates a repair mechanism may have occurred shortly after treatment in our real-time image 
study (see Sections 2 (a) to (c)). This hypothesis was supported by the IncuCyte proliferating cell curves over a 
period of 35 hours after treatment (specifically, Section 2b)). For MCF-7, the fluctuation for the rate of growth 
change in the curve also indicates a potential repair process occurring (see Fig. 6b). The rate of change in the 
cells proliferation increases more rapidly towards the end of the 35-hour experiment period, which in this case 
corresponds to the confluence value converging to the control cell number in the mEHT treatment group as seen 
in Fig. 6a. The marginal deviations in the rate of change for cell growth seen in Fig. 6b for MCF-7 did not occur 
for 9 L, which exhibited a near monotonic increase in the rate of cell growth change (see Fig. 5b). Although this 
behaviour is vastly different to MCF-7, the ultimate outcome is the same: the cell confluence for both cell lines 
appear to be converging to the control value of 1, which in turn is the resumption of normal cell growth. Thus 
for a short-term timespan, there is no indication of an obvious advantage of mEHT as a standalone treatment 
method. These results contradict the findings for the mEHT cell damaging process, which has been repeatedly 
shown in numerous publications to date4,23,24. The referred damage process is the permanent damage in the cell 
morphology that in parallel caused the cells to undergo apoptosis within the initial 48 hours after the mEHT 
treatment24. At the time frame between 8 to 24 hours in the process is marked as the pivotal point where the cells 
are committed to die24,25.
According to the literature, the time delay in the selection and the tumour destruction of mEHT is due to 
apoptosis23,26. It has been repeatedly shown that the detection of apoptosis on the mEHT treated cells is evi-
dent27,28. Andocs et al. demonstrate this on U937 cell line using DNA fragmentation assay after 3 hours of treat-
ment27. Yang et al. demonstrated this using FITC-conjugated Annexin V and propidium iodine reagents with 
different types of malignant cells 24 hours after treatment, which include MCF-7 and also a brain tumour cell 
line (U87MG)28. Our real-time imaging studies immediately post-treatment in Sections 2a) to 2c) are limited to 
assessing only the physical outcome. It is customised to observe the potential occurrence of apoptosis. However, 
clonogenic assay is our selected tool for assessing programmed cell death (i.e., beyond the possibility of cell repro-
duction). The results showed a lower survival fraction for both malignant (9 L and MCF-7) and healthy (MDCK) 
cell lines which indicate that cells underwent apoptosis. Although the clonogenic assay outcomes were positive 
Figure 7. Normalised survival fractions of MDCK, 9 L and MCF-7 cell lines following 30-minute exposure to 
mEHT. Clonogenic assay was performed on both untreated (control) and treated cells for the three cell lines. 
The assay was performed at least 3 times. Errors bars represent the SEM.
www.nature.com/scientificreports/
1 0SCIeNTIfIC REPORTs |         (2018) 8:16608  | DOI:10.1038/s41598-018-34712-0
in regards to inducing apoptosis for both malignant cell lines, it also unfavourably targeted the benign cell line, 
which raises some doubts on mEHT’s selectivity characteristic.
Experimental results reported by Szasz et al. on different cancerous cells co-cultured with non-cancerous cells 
demonstrated a complete disappearance of malignant cells by 24 hours in their most aggressive cell line, which is 
A431 squamous carcinoma cell line4. Our study did not show this same effect on the aggressive 9 L cell line that 
was co-cultured with MDCK cells for 96 hours as seen in Fig. 5. We hypothesise the occurrence of a stronger 
repair mechanism for 9 L compared to the A431 cell line in this time span. The A431 cell line is derived from epi-
dermoid carcinoma in the human skin. Epidermoid carcinoma cells are generally radiosensitive and chemosen-
sitive29. This suggests that the repair mechanism for the A431 cell line may not be as highly active in comparison 
Figure 8. Clonogenic cell survival assay was performed on (a) MDCK (b) 9 L and (c) MCF-7 cells following 
30-minutes exposure to mEHT and 10MV irradiation at 5 Gy, with and without individual components of the 
combination. The assay was performed twice. Errors bars represent the SEM.
www.nature.com/scientificreports/
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to 9 L. MCF-7 cells are less aggressive than 9 L cells and thus the co-existence of MCF-7 with MDCK cells result in 
Fig. 6 is consistent with experimental results reported by Szasz et al. for their non- aggressive malignant cell line4.
Although the supposed benefits of mEHT as a sole method of treatment are moderately observed, the greater 
potential of mEHT lies in multimodal therapies (chemotherapy and hyperthermia is the most common multi-
modal treatment) context in treating malignant cells. The initial damage on the 9 L cells’ membrane (and poten-
tially, the cell overall) as seen in the PI staining image in Fig. 2 immediately after mEHT treatment (i.e., at the 
0 hour) creates a window of opportunity to integrate other treatment modalities. Thus, this marks the timing 
of our radiation to be near immediately (i.e., 15 minutes) after the mEHT treatment. This also marks the first 
instance of mEHT’s selectivity being observed in this research. In corresponding to the aforementioned observed 
initial damage of 9 L cell membrane at the 0 hour, the MDCK cell line is seen to be immune to the mEHT treat-
ment. This is highlighted by no evident difference between the control group and mEHT treated group on MDCK 
(see Fig. 1).
For this research, the most significant sighting of selectivity from the mEHT treatment is observed when com-
bined with 10 MV radiation in Section 2e). The observed selectivity is evident for the 9 L cells SF results. MCF-7 
cells are radiosensitive but the effectiveness of the combined treatment was not expected in this study because the 
point of radiation (i.e., the timing) used was based on the results we obtained for 9 L and findings in literature30. 
In particular, the results from Section 2a) reflect this. It is possible that the absence of a lower survival fraction 
in MCF-7 in this multimodal treatment is due to the time gap between applying mEHT and radiation as data in 
section 2d) hints at a more long-term effect of mEHT.
The 9 L cells showed a supra-additive effect. We hypothesize that this is caused by mEHT allowing for the 
initial damage to the cancerous cells, which in turn allow for the free radicals generated from radiation to freely 
enter the cells and effectively induce cell death (i.e., apoptosis). This is a significant result because 9 L is a type of 
tumour that is closely related to glioblastoma, the most fatal form of brain cancer31. Additionally, there is cur-
rently no effective treatment for this tumour type, not even in multimodal treatments. The experimental results 
find mEHT to complement radiotherapy quite well. This is consistent with the literature that shows that mEHT 
therapy is most effective when combined with conventional treatments4,26. Hence, this proves to be a promising 
candidate of treatment for this type of cancer (i.e., glioblastoma).
Moreover, our results demonstrate a new exciting prospect for mEHT treatment. In particular, mEHT induced 
a rapid increase in the cell growth rate of the radioresistant 9 L cell line. This is significant because mEHT appears 
to provide a new tool to manipulate the cells’ growth rate. This in turn modifies these types of radioresistant cells 
to be more radiosensitive, which allow them to be a stronger candidate for radiotherapy. Recall that one of fun-
damental laws of radiobiology states that an increased cell growth rate will result in greater radiosensitivity in the 
tissue. Thus, we believe that this new tentative path for mEHT research should be pursued more actively.
All the mEHT literature results demonstrate only a short-term response in the cells to the treatment in vitro. 
The experiments and analyses conducted in this work focused on the physical outcome of the mEHT treatment 
on the cells. The main component of this research is to assess the effectiveness of the mEHT treatment based on 
the cells’ radiobiological “endpoint”, which has never been performed before. The two main experimental meth-
odologies employed in this research are real-time imaging and clonogenic assay. The aforementioned methodol-
ogies are less dependent on artefacts, as opposed to the methods utilised by other mEHT studies. The advantage 
of this is that the results we obtain are interpreted more easily. In particular, with clonogenic assay as this is con-
sidered the gold standard in radiobiology.
In summary, no benefit of mEHT treatment alone was observed in this study. However, the combined mEHT 
treatment with radiation therapy on the most aggressive and radioresistant malignant cells produced a significant 
increase in cell death. The results show the potential of this combined treatment modality in some, but not all, 
tumours cell lines. The most significant insight gained from the mEHT treatment is in its apparent potential to 
manipulate the cell growth rate. Specifically, on the radioresistant 9 L cell line (which is closely related to glioblas-
toma). This new aspect of mEHT treatment shows promise as the cells’ growth rate is closely tied to its radiosensi-
tivity. Further study to support the results ascertained is encouraged to fully establish whether mEHT has a direct 
influence on the cell growth rate. Additionally, the present work provides the first set of independent data that is 
not based on external results or methods from other literature in the field. Future research also could include the 
investigation and analysis of this combined treatment method and the use of other cell lines.
Materials and Methods
Cell Culture. Gs-9L rat gliosarcoma cells originated from an N-nitrosomethylurea-induced tumour and were 
established by the European Collection of Cell Cultures. Madin-Darby canine kidney is a non-cancerous cells line 
(MDCK), derived in 1958 by S.H. Madin and N.B. Darby from the kidney tissue of an adult female cocker spaniel. 
MCF-7 cells line is derived from a pleural effusion from a patient with metastatic breast cancer. Cell cultures were 
maintain in Dulbecco’s Modified Eagle medium (DMEM, Gibco BRL, AUS) containing 10% (v/v) fetal bovine 
serum (FBS, Sigma-Aldrich, MO, USA) and 1% (v/v) penicillin/streptomycin (Pen Strep, Gibco BRL, AUS) in 
a T75 cm2 BD FalconTM Tissue Culture Flasks (Franklin Lakes, NJ, USA) and incubated at 37 °C in a humidified 
and 5% (v/v) CO2 atmosphere.
mEHT treatment procedure. Cells were grown and passaged using T75 cm2 BD FalconTM Tissue Culture 
Flasks. Confluent cells were washed with Phosphate-Buffered Saline (Ca2+/Mg2+ free) (PBS, Gibco BRL, AUS), 
detached using Trypsin- ethylenediaminetetraactic acid (Trypsin-EDTA, Gibco BRL, AUS) and rediluted in 
complete DMEM before evenly distributed into 2 ml cryogenic tubes. The mEHT sample tubes were exposed 
to mEHT via the LAB-EHY 100 laboratory unit and in vitro applicator (Oncotherm GmbH, Germany) at 42 °C 
for 30 minutes. Temperature was controlled real time via calibrated thermocouples. The control sample tubes 
were at room temperature during the short time between getting the samples from one incubator to the next. 
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This practice is carried out to maintain a controlled environment from the time the treatment samples leave the 
incubator (set at 37 °C) and returning to the incubator (also set to 37 °C) after the treatment has been applied. 
Apart from very short transit period, all the samples (both control and treatment) are cultured in the incubator 
at the definite 37 °C.
Confocal Microscope Imaging of cells stained with Propidium iodine. The cells were seeded and 
grown in a TMLab-TekTMII Chamber SlideTMSystem 4 wells (growth area = 1.8 cm2) after applied mEHT treat-
ment. The cells were incubated at 37 °C until taken for imaging using a Leica confocal laser scanning microscope. 
Immediately prior to imaging, the cells were washed with PBS (Ca2+/Mg2+ free), and 200 mL PI master mix 
(100 mg/ml RNase A, 40 mg/mL PI, and PBS pH 7.4) was added to the cells. Light and fluorescence microscope 
images were obtained using a Leica confocal laser scanning microscope (Leica TCS SP5 Advanced System – 
UV-VIS-IR and X1-Port Access with SMD FCS and CO2 incubation chamber, Germany) with oil immersion 
objective lens and at the excitation of 488 nm.
IncuCyte Imager and data analysis. IncuCyte images were taken to assess the growth rate (proliferation) 
of the cells pre-treated with mEHT. The results were normalised to the control (untreated cells). This experiment 
was carried out to investigate if the apoptosis induced by mEHT affects the cell proliferation during the period 
shortly after the treatment. Each of the recorded data values are normalised to their corresponding control value 
to give a better comparison between the treatment group results. The errors bars are standard errors of the means 
(SEM). The experiments were performed three times independently.
Co-culture. The key claim in mEHT treatment is the selectivity function on malignant cells. IncuCyte imager 
was employed to assist in this assessment. Prior to the mEHT treatment, the malignant (9 L or MCF-7) and 
non-malignant (MDCK) cell lines are transferred into the same tube. The type of tube and the volume of the cell 
solution is the same as used in all other experiments previously described. Similarly, the mEHT treatment setup 
is the same as the other experiments. After mEHT treatment, the co-cultured non-malignant cells (MDCK) 
and malignant cells (9 L or MCF-7) at the same cell density as the controls (co-cultured cells without mEHT 
treatment) were seeded into the wells and imaged every 24 hours over 96 hours. Different cell lines have different 
proliferation rates (doubling time) and this was accounted for in the preparation of the co-cultured cells prior to 
apply the mEHT treatment for imaging. Results are as shown in Fig. 5 for co-culture of MDCK and 9 L cells and 
in Fig. 6 for co-culture of MDCK and MCF-7 cell.
Irradiation procedure and set up. mEHT pre-treated cells and untreated cells were irradiated with 10 MV 
photon beams from a Versa HD linear accelerator (Elekta, Stockholm, Sweden) at a dose of 5 Gy. We selected a 
gap of 15 minutes between the mEHT treatment and the exposure of radiation taking into account two factors. 
The first is based on the PI staining results of 9 L. The second is we deemed 15 minutes to be a feasible time gap 
when considering a clinical treatment. The cryogenic tubes were placed vertically at a depth of 2.2 cm in solid 
water to match the maximum depth dose of the 10MV photon field. To maintain full scatter conditions, 10 cm of 
solid water was placed behind the flask with 2 cm solid water around its sides.
Clonogenic Assay Survival Fraction and data analysis. The efficiency of the treatments was assessed 
using clonogenic survival assay as the radiobiological endpoint. The clonogenic cell survival assays is employed to 
determine cell death through loss of reproductive integrity and the ability to proliferate indefinitely.
Cells were plated after the applied treatment at low densities in 100 mm tissue culture dishes containing 10 ml 
of complete DMEM. Each sample involved a minimum of three cells densities with triplicate dishes for each 
density. After 15 doubling times, the colonies in the dishes were fixed and stained with a solution of 25% crystal 
violet and 75% ethanol.
A colony was considered as surviving if it contained more than 50 cells. The plating efficiency (PE) was calcu-
lated as the number of surviving colonies divided by the number of cells seeded. The number of colonies that arise 
after treatment, which is expressed in terms of PE, is called the cell clonogenic survival fraction (SF):
=SF treated cells PE treated cells
PE untreated cells
( ) ( )
( )
The errors bars are standard errors of the means (SEM). The assays of all treatment conditions (with or without 
mEHT/radiation treatment) were performed a minimum of three times independently.
Data Availability Statement
No specific data availability circumstances are required for this work. All experimental protocols are self-con-
tained, and the relevant datasets are disclosed throughout the article.
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